Sometimes hindsight may not always be such a wonderful thing, especially for Human Genome Sciences (HGSI). The drug developer, which agreed to be bought by GlaxoSmithKline (GSK) earlier this month for $14.25 per share, says it received and rejected a much higher $35 per share takeover bid by Amgen (AMGN) back in August, 2010. It decided not to sell at the time because regulatory approval for its lupus drug Benlystsa was expected later that year. Ah, if only...
Sometimes hindsight may not always be such a wonderful thing, especially for Human Genome...
From other sites
Video at CNBC.com (Oct 13, 2016)
Video at CNBC.com (Sep 18, 2016)
Video at CNBC.com (Sep 7, 2016)
Video at CNBC.com (Aug 1, 2016)
Video at CNBC.com (Jul 27, 2016)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs